Antiplaque/antigingivitis FDA combination policy endorsed by plaque group.
This article was originally published in The Rose Sheet
Executive Summary
ANTIPLAQUE/ANTIGINGIVITIS COMBINATION POLICY ENDORSED by FDA's Dental Plaque Subcommittee at its meeting May 29 in Gaithersburg, Md. The sub-committee concluded that anticaries and tooth desensitizing agents could be combined appropriately with an approved antiplaque/antigingivitis ingredient or ingredient combination.